|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
August 2006FeaturesCover Story Applying the Carrot-and-Stick Approach to BiotechLong the cornerstone of formulary building, preferred-product designations are emerging within classes of biotech therapies. Still in its infancy, this phenomenon is a logical if not unexpected step, but choosing a preferred specialty drug is far more complicated than doing the same for traditional therapies. Show Me the Evidence!For some patients with previously untreatable conditions,
old-style therapies struck out. Biologic therapies promise a home run just about every time to the plate, but how does a payer size up the heavy hitters? Q&A An Interview with Steven E. McKenzie, MD, PhDJefferson’s McKenzie is tasked with taking a leadership role in biomedical research. The payoff? Lasting improvements in med ed and patient care. Therapy Optimization: A New Model for Managing High-Cost BiologicsUsing MS as an example, Thomas Morrow, MD, offers a paradigm by which specialty pharmacies can provide therapy-tracking services. Bio Blog Traveling a Long and Winding Road Toward Personalized MedicineJust how robust is the biotech pipeline? Will the emergence of competitive biologic therapies create a market? Our man at BIO asked — and got answers. DepartmentsOpeners You’re Kidding Me, Right?
Michael D. Dalzell Editorial Guanxi!
David B. Nash, MD, MBA Washington Watch Transgenics Finally Gets First Regulatory OK
John Carroll Diagnostics and Devices Oncotype DX Test Offers Guidance for Women Debating ChemotherapyBetter biomarkers for breast cancer. Drug Track Approvals, FDA Actions, Clinical Trials
Bob Carlson, MHA Biotech Business ‘Generic’ Biotech Products: Are the Floodgates Open? At Whose Expense?
Amanda Brower Conference Coverage 7th Annual European Congress of Rheumatology
John Otrompke, JD Trends: Utilization More Drugs for More Uses Drive Specialty Spending Growth
Katherine T. Adams |
|||||